These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29326922)

  • 1. Patterns and Gaps Identified in a Systematic Review of the Hepatitis C Virus Care Continuum in Studies among People Who Use Drugs.
    Jordan AE; Perlman DC; Reed J; Smith DJ; Hagan H
    Front Public Health; 2017; 5():348. PubMed ID: 29326922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis.
    Reed JR; Jordan AE; Perlman DC; Smith DJ; Hagan H
    Syst Rev; 2016 Jul; 5(1):110. PubMed ID: 27401499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
    Jordan AE; Cleland CM; Schackman BR; Wyka K; Perlman DC; Nash D
    J Infect Dis; 2020 Sep; 222(Suppl 5):S335-S345. PubMed ID: 32877560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis.
    Oru E; Trickey A; Shirali R; Kanters S; Easterbrook P
    Lancet Glob Health; 2021 Apr; 9(4):e431-e445. PubMed ID: 33639097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium.
    Busschots D; Kremer C; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Windelinckx T; Maertens G; Bourgeois S; Hens N; Matheï C; Robaeys G
    Harm Reduct J; 2021 May; 18(1):54. PubMed ID: 34001145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique.
    Semá Baltazar C; Kellogg TA; Boothe M; Loarec A; de Abreu E; Condula M; Fazito E; Raymond HF; Temmerman M; Luchters S
    Int J Drug Policy; 2021 Apr; 90():103095. PubMed ID: 33429163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment.
    Talal AH; George SJ; Talal LA; Dharia A; Ventuneac A; Baciewicz G; Perumalswami PV; Dickerson SS
    Res Involv Engagem; 2023 Aug; 9(1):63. PubMed ID: 37533127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses.
    Zhou K; Fitzpatrick T; Walsh N; Kim JY; Chou R; Lackey M; Scott J; Lo YR; Tucker JD
    Lancet Infect Dis; 2016 Dec; 16(12):1409-1422. PubMed ID: 27615026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reflex Hepatitis C Virus Viral Load Testing Following an Initial Positive Hepatitis C Virus Antibody Test: A Global Systematic Review and Meta-analysis.
    Tao Y; Tang W; Fajardo E; Cheng M; He S; Bissram JS; Hiebert L; Ward JW; Chou R; Rodríguez-Frías F; Easterbrook P; Tucker JD
    Clin Infect Dis; 2023 Oct; 77(8):1137-1156. PubMed ID: 37648655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis.
    Levander XA; Vega TA; Seaman A; Korthuis PT; Englander H
    Subst Abus; 2022; 43(1):245-252. PubMed ID: 34161198
    [No Abstract]   [Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study.
    Ryan P; Valencia J; Cuevas G; Troya J; Torres-Macho J; Muñoz-Gómez MJ; Muñoz-Rivas N; Canorea I; Vázquez-Morón S; Resino S
    Infect Dis Poverty; 2021 Aug; 10(1):111. PubMed ID: 34412695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C.
    Nagot N; D'Ottavi M; Quillet C; Debellefontaine A; Castellani J; Langendorfer N; Hanslik B; Guichard S; Baglioni R; Faucherre V; Tuaillon E; Pageaux GP; Laureillard D; Donnadieu-Rigole H
    Open Forum Infect Dis; 2022 Jun; 9(6):ofac181. PubMed ID: 35774932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National HIV and HCV Screening Rates for Hospitalized People who Use Drugs Are Suboptimal and Heterogeneous Across 11 US Hospitals.
    Westgard LK; Sato T; Bradford WS; Eaton EF; Pilcher F; Hale AJ; Singh D; Martin M; Appa AA; Meyer JP; Weimer MB; Barakat LA; Felsen UR; Akiyama MJ; Ridgway JP; Grussing ED; Thakarar K; White A; Mutelayi J; Krsak M; Montague BT; Nijhawan A; Balakrishnan H; Marks LR; Wurcel AG
    Open Forum Infect Dis; 2024 May; 11(5):ofae204. PubMed ID: 38746950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review.
    Socías ME; Karamouzian M; Parent S; Barletta J; Bird K; Ti L
    Int J Drug Policy; 2019 Oct; 72():146-159. PubMed ID: 31147142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review.
    Kronfli N; Linthwaite B; Kouyoumdjian F; Klein MB; Lebouché B; Sebastiani G; Cox J
    Int J Drug Policy; 2018 Jul; 57():95-103. PubMed ID: 29715590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One or two serological assay testing strategy for diagnosis of HBV and HCV infection? The use of predictive modelling.
    Parry JV; Easterbrook P; Sands AR
    BMC Infect Dis; 2017 Nov; 17(Suppl 1):705. PubMed ID: 29143611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.